Bank of America’s Sarepta Therapeutics SRPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-14,900
| Closed | -$951K | – | 8652 |
|
|
2025
Q1 | $951K | Sell |
14,900
-5,100
| -26% | -$537K | ﹤0.01% | 5256 |
|
|
2024
Q4 | $2.43M | Buy |
20,000
+13,200
| +194% | +$1.62M | ﹤0.01% | 4279 |
|
|
2024
Q3 | $849K | Sell |
6,800
-23,000
| -77% | -$3.18M | ﹤0.01% | 5164 |
|
|
2024
Q2 | $4.71M | Sell |
29,800
-69,200
| -70% | -$8.89M | ﹤0.01% | 3676 |
|
|
2024
Q1 | $12.8M | Buy |
+99,000
| New | +$12.1M | ﹤0.01% | 2727 |
|
|
2023
Q4 | – | Sell |
-94,800
| Closed | -$11.5M | – | 8216 |
|
|
2023
Q3 | $11.5M | Buy |
+94,800
| New | +$10.7M | ﹤0.01% | 2594 |
|
|
2023
Q2 | – | Sell |
-61,500
| Closed | -$8.48M | – | 7932 |
|
|
2023
Q1 | $8.48M | Buy |
+61,500
| New | +$7.98M | ﹤0.01% | 2992 |
|
|
2022
Q3 | – | Sell |
-19,100
| Closed | -$1.43M | – | 8178 |
|
|
2022
Q2 | $1.43M | Buy |
+19,100
| New | +$1.41M | ﹤0.01% | 4590 |
|
|
2021
Q1 | – | Sell |
-22,300
| Closed | -$3.8M | – | 7753 |
|
|
2020
Q4 | $3.8M | Buy |
22,300
+18,400
| +472% | +$2.73M | ﹤0.01% | 3378 |
|
|
2020
Q3 | $548K | Buy |
+3,900
| New | +$593K | ﹤0.01% | 4646 |
|
|
2020
Q2 | – | Sell |
-17,100
| Closed | -$1.67M | – | 7111 |
|
|
2020
Q1 | $1.67M | Sell |
17,100
-7,900
| -32% | -$903K | ﹤0.01% | 3623 |
|
|
2019
Q4 | $3.23M | Sell |
25,000
-11,700
| -32% | -$1.18M | ﹤0.01% | 3619 |
|
|
2019
Q3 | $2.76M | Sell |
36,700
-22,400
| -38% | -$2.65M | ﹤0.01% | 3766 |
|
|
2019
Q2 | $8.98M | Buy |
59,100
+58,300
| +7,288% | +$7.09M | ﹤0.01% | 2661 |
|
|
2019
Q1 | $95K | Sell |
800
-234,300
| -100% | -$30.1M | ﹤0.01% | 5908 |
|
|
2018
Q4 | $25.7M | Buy |
235,100
+190,100
| +422% | +$23.8M | ﹤0.01% | 1484 |
|
|
2018
Q3 | $7.27M | Hold |
45,000
| – | – | ﹤0.01% | 2828 |
|
|
2018
Q2 | $5.95M | Sell |
45,000
-4,000
| -8% | -$377K | ﹤0.01% | 2982 |
|
|
2018
Q1 | $3.63M | Buy |
+49,000
| New | +$3.27M | ﹤0.01% | 3375 |
|
|
2017
Q2 | – | Sell |
-19,000
| Closed | -$562K | – | 7156 |
|
|
2017
Q1 | $562K | Buy |
+19,000
| New | +$588K | ﹤0.01% | 4810 |
|
|
2016
Q3 | – | Sell |
-250,000
| Closed | -$4.77M | – | 7332 |
|
|
2016
Q2 | $4.77M | Buy |
+250,000
| New | +$4.63M | ﹤0.01% | 2830 |
|
|
2015
Q1 | – | Sell |
-6,500
| Closed | -$94K | – | 7521 |
|
|
2014
Q4 | $94K | Sell |
6,500
-53,600
| -89% | -$908K | ﹤0.01% | 5934 |
|
|
2014
Q3 | $1.27M | Buy |
60,100
+48,900
| +437% | +$1.1M | ﹤0.01% | 3794 |
|
|
2014
Q2 | $334K | Sell |
11,200
-13,300
| -54% | -$420K | ﹤0.01% | 5023 |
|
|
2014
Q1 | $589K | Buy |
24,500
+5,500
| +29% | +$140K | ﹤0.01% | 4439 |
|
|
2013
Q4 | $387K | Buy |
19,000
+6,700
| +54% | +$199K | ﹤0.01% | 4983 |
|
|
2013
Q3 | $581K | Buy |
12,300
+3,200
| +35% | +$123K | ﹤0.01% | 4481 |
|
|
2013
Q2 | $346K | Buy |
+9,100
| New | +$325K | ﹤0.01% | 5100 |
|
Other funds holding SRPT
VPM
VCM
RCM
EAM
Bank of America's SRPT Position: Q1 2026 in Review
Bank of America increased its Sarepta Therapeutics (SRPT) stake by 27% in Q1 2026, buying an estimated $8.74M and bringing the position to 2,145,926 shares worth $46.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1647.
Bank of America first reported a position in SRPT in Q2 2013 and has held it in 52 quarters since. The position peaked at $117M in Q4 2023. 341 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.
- Bank of America held 2,145,926 shares of Sarepta Therapeutics worth $46.7M as of Q1 2026.
- Bank of America bought 451,336 Sarepta Therapeutics shares in Q1 2026, an estimated $8.74M.
- Sarepta Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #1647 holding.
- Bank of America first reported a position in Sarepta Therapeutics in Q2 2013 and has held it in 52 quarters since.
- Bank of America's Sarepta Therapeutics position peaked at $117M in Q4 2023.
- 341 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.
Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.